Values First Advisors Inc. Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Values First Advisors Inc. grew its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 20.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 29,009 shares of the biopharmaceutical company’s stock after purchasing an additional 4,837 shares during the period. Values First Advisors Inc.’s holdings in Celldex Therapeutics were worth $733,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. KBC Group NV increased its holdings in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 495 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Celldex Therapeutics by 23.7% in the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 1,504 shares during the period. Point72 DIFC Ltd raised its holdings in shares of Celldex Therapeutics by 101.7% during the third quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 7,116 shares during the last quarter. Creative Planning bought a new position in Celldex Therapeutics during the third quarter valued at approximately $504,000. Finally, GSA Capital Partners LLP boosted its holdings in Celldex Therapeutics by 191.2% in the third quarter. GSA Capital Partners LLP now owns 16,114 shares of the biopharmaceutical company’s stock worth $548,000 after purchasing an additional 10,581 shares during the last quarter.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $22.26 on Thursday. Celldex Therapeutics, Inc. has a one year low of $20.91 and a one year high of $53.18. The business has a fifty day moving average price of $24.93 and a 200-day moving average price of $30.08. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -8.66 and a beta of 1.60.

Wall Street Analyst Weigh In

CLDX has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $62.25.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.